Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

MR Ananda-Rajah; A Grigg; MT Downey; A Bajel; T Spelman; A Cheng; KT Thursky; J Vincent; MA Slavin

Journal article

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

MR Ananda-Rajah, A Grigg, MT Downey, A Bajel, T Spelman, A Cheng, KT Thursky, J Vincent, MA Slavin

Haematologica | FERRATA STORTI FOUNDATION | Published : 2012

DOI: 10.3324/haematol.2011.051995

Abstract

Post-induction aplasia for acute myeloid leukemia/myelodysplastic syndrome is a high-risk period for invasive fungal diseases. The effectiveness of fluconazole, itraconazole solution, voriconazole and posaconazole prophylaxis used consecutively from December 1998 to January 2010 in patients with acute myeloid leukemia/ myelodysplastic syndrome undergoing remission-induction chemotherapy was retrospectively evaluated. A total of 216 consecutive patients received 573 prophylaxis courses. Breakthrough-invasive fungal disease incidence in fluconazole, itraconazole, voriconazole, posaconazole recipients was 25%, 16%, 14% and 3%, respectively. Voriconazole/posconazole versus fluconazole/itraconazo..

View full abstract

University of Melbourne Researchers

Ashish Bajel Author

Timothy Spelman Author

Kas Thursky Author

Monica Slavin Author

Grants

Funding Acknowledgements

Funding: National Health and Medical Research Council post-graduate medical scholarship to MA-R. This study received no external funding. Manuscript received on July 20, 2011. Revised version arrived on October 17, 2011. Manuscript accepted on October 17, 2011.